In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Editas Medicine (EDIT – Research Report), ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...

Oppenheimer analyst Jay Olson maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Hold rating on Editas Medicine (EDIT – Research Report), with a ...

Analyst Yanan Zhu of Wells Fargo maintained a Buy rating on Editas Medicine (EDIT – Research Report), with a price target of $9.00. Yanan ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

JonesTrading analyst Soumit Roy has assigned their bullish stance on EDIT stock, giving a Buy rating today. Soumit Roy’s rating is based ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

Co-hosted by UC Santa Barbara Arts & Lectures and the Cancer Foundation of Santa Barbara, the talk will discuss CRISPR-Cas9 ...

JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara host the Nobel Prize–winning biochemist for a talk on CRISPR ...

Plunkitt of Tammany Hall,” a collection of political sermons attributed to a crooked machine boss, is a handy reference for ...